The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2021 | CAR-T patient experience: results from the Global Patient Survey
Lorna Warwick, Lymphoma Coalition, Toronto, Canada, discusses the Lymphoma Coalition Bi-Annual Global Patient Survey and the small-scale results of patients that have undergone CAR T-cell therapy. Ms Warwick highlights the differences in the dataset between patients who were qualified for CAR-T therapy but had not yet received it and those that had completed CAR T-cell therapy, as well as the impact of CAR T-cell therapy on patients’ mental health. Ms Warwick also suggests educating patients about CAR T-cell therapy could help address these problems. This interview took place during the 3rd European CAR T-cell Meeting.
